Phase I study of immunotherapy with methanol extraction residue (MER) of bacillus Calmette-Guérin.
D000038:Abscess / Q000209:etiology; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005591:Chemical Fractionation; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D000432:Methanol; D009369:Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D000432:Methanol